Loading...
High-dose cyclosporine A (CSA) is a mainstay in immunosuppressive treatment of solid-organ transplant recipients. Low-dose CSA has been used successfully to treat nearly a dozen dermatologic disorders; its most common dermatologic use is as an alternative to methotrexate for psoriasis and psoriatic erythroderm.
These investigators from Italy report the results of an uncontrolled trial of oral low-dose CSA therapy in 293 patients with generalized or severe plaque psoriasis and 33 patients with erythrodermic psoriasis. Patients with renal disease, uncontrolled hypertension or previous neoplasms, or those who were unlikely to complete the study were excluded. The initial CSA dose was 3 or 5 mg/kg/day for at least 2 to 3 months; when the maximal…